VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Forum: Aktien Thema: Hauptdiskussion

ok, sorry mein Fehler. Aber zumindest ist man nun weniger optimistisch und denkt nicht mehr in Quartals sondern in Jahren

Brasilien Zulassung wird 2025 erwartet…

Muss aber an ein Meeting Schöne Tag

Hätte noch etwa 20 Seiten........

institute-of-india/) 6 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate - Valneva (https://valneva.com/press-release/valneva-and-limmatech- enter-into-a-strategic-partnership-to-accelerate-the-development-of-the-worlds- most-clinically-advanced-tetravalent-shigella-vaccine-candidate/) 7 Valneva Announces New IXIARO (https://valneva.com/press-release/valneva- announces-new-ixiaro-supply-contract-with-the-u-s-government-worth-a-minimum-of- 32-8-million/)(®) (https://valneva.com/press-release/valneva-announces-new- ixiaro-supply-contract-with-the-u-s-government-worth-a-minimum-of-32-8-million/) Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Valneva (https://valneva.com/press-release/valneva-announces-new-ixiaro-supply- contract-with-the-u-s-government-worth-a-minimum-of-32-8-million/) 8 For additional information on Adjusted EBITDA, please refer to the 'Non-IFRS Financial Measures' section at the end of the PR 9 Valneva Announces New IXIARO (https://valneva.com/press-release/valneva- announces-new-ixiaro-supply-contract-with-the-u-s-government-worth-a-minimum-of- 32-8-million/)(®) (https://valneva.com/press-release/valneva-announces-new- ixiaro-supply-contract-with-the-u-s-government-worth-a-minimum-of-32-8-million/) Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - Valneva (https://valneva.com/press-release/valneva-announces-new-ixiaro-supply- contract-with-the-u-s-government-worth-a-minimum-of-32-8-million/) 10 Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium. 11 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-announces-u-s-fda-approval-of- worlds-first-chikungunya-vaccine-ixchiq/)(®) (https://valneva.com/press- release/valneva-announces-u-s-fda-approval-of-worlds-first-chikungunya-vaccine- ixchiq/) - Valneva (https://valneva.com/press-release/valneva-announces-u-s-fda- approval-of-worlds-first-chikungunya-vaccine-ixchiq/)

Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-receives- marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine- ixchiq/)(®) (https://valneva.com/press-release/valneva-receives-marketing- authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/) - Valneva (https://valneva.com/press-release/valneva-receives-marketing- authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/) 13 Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-announces-health- canada-approval-of-the-worlds-first-chikungunya-vaccine-ixchiq/)(®) (https://valneva.com/press-release/valneva-announces-health-canada-approval-of- the-worlds-first-chikungunya-vaccine-ixchiq/) - Valneva (https://valneva.com/press-release/valneva-announces-health-canada-approval-of- the-worlds-first-chikungunya-vaccine-ixchiq/) 14 Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-receives- marketing-authorization-in-the-uk-for-the-worlds-first-chikungunya-vaccine- ixchiq/)(®) (https://valneva.com/press-release/valneva-receives-marketing- authorization-in-the-uk-for-the-worlds-first-chikungunya-vaccine-ixchiq/)

15 Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ (https://valneva.com/press-release/valneva- receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for- chikungunya-vaccine-ixchiq/)(®) (https://valneva.com/press-release/valneva- receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for- chikungunya-vaccine-ixchiq/) - Valneva (https://valneva.com/press- release/valneva-receives-emas-positive-chmp-opinion-for-adolescent-label- extension-for-chikungunya-vaccine-ixchiq/) 16 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine - Valneva (https://valneva.com/press-release/cepi-expands-partnership-with-valneva-with-a- 41-3-million-grant-to-support-broader-access-to-the-worlds-first-chikungunya- vaccine/) 17 Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - Valneva (https://valneva.com/press-release/valneva- successfully-expands-access-to-asia-for-its-chikungunya-vaccine-with-serum

Für welche Zeit haben .... 18 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - Valneva (https://valneva.com/press- release/phase-3-valor-lyme-disease-trial-valneva-and-pfizer-announce-primary- vaccination-series-completion/) 19 https://valneva.com/press-release/valneva-and-pfizer-report-further-positive- phase-2-booster-results-for-lyme-disease-vaccine-candidate/ 20 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases (https://valneva.com/press-release/valneva-announces- publication-of-lyme-disease-phase-2-trials-in-the-lancet-infectious-diseases/) 21 Shigellosis | CDC Yellow Book 2024 (https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/shigellosis) 22 Immunization, Vaccines and Biologicals (who.int) (https://www.who.int/teams/immunization-vaccines-and-

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V - Valneva (https://valneva.com/press- release/valneva-and-limmatech-awarded-fda-fast-track-designation-for- tetravalent-shigella-vaccine-candidate-s4v/) 24 Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 (https://valneva.com/press- release/valneva-and-limmatech-announce-first-vaccination-in-phase-2b-human- challenge-study-of-tetravalent-shigella-vaccine-candidate-s4v2/) 25 LEK analysis 26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - Valneva (https://valneva.com/press-release/valneva-initiates-phase-1-trial-of- second-generation-zika-vaccine-candidate/) 27 Zika virus disease (who.int) (https://www.who.int/health-topics/zika-virus- disease) 28 Tropical Disease Priority Review Voucher Program | FDA (https://www.fda.gov/about-fda/center-drug-evaluation-and-research- cder/tropical-disease-priority-review-voucher-program) 29 The audit procedures on the consolidated financial statements have been performed. The audit report will be issued upon finalization of procedures regarding the filing.

Für die Franzosen 20 mars (Reuters) - La société française de biotechnologie Valneva a déclaré jeudi s'attendre à des ventes de 170 à 180 millions d'euros en 2025, générant des flux de trésorerie positifs pour l'ensemble des activités commerciales. "Avec plus de 168 millions d'euros de trésorerie à la fin 2024, nous abordons 2025 dans une bonne position financière pour soutenir ces objectifs", a déclaré dans un communiqué Peter Bühler, directeur financier de Valneva. La société a publié des ventes de 163,3 millions d'euros en 2024. Le groupe a fait également état d'une perte de 12,2 millions d'euros en 2024, contre une perte de 101,4 millions d'euros en 2023.

gleiches Spiel wie damals beim Corona Impfstoff. Da hat man auch geschrieben, dass es genug Länder gibt, die an dem Impfstoff interessiert sind und man Gespräche mit diesen Löndern führt. Die Ergebnisse und welche Länder das waren wurde bis heute nie kommuniziert

Man hätte auch als Überschrift schreiben können: „Wir sind pleite und sind eine Kack-Firma“. Lustig, dass man letztes Jahr noch mehrfach geschrieben hat, dass die Zulassung in Brasilen in Q4 erwartet wird, dann hieß es Q1 und jetzt wird nichts mehr dazu geschrieben. Kein Wort darüber, warum die Erwartung nicht eingetroffen ist. Hauptsache es hört sich erstmal toll an um die Aktionäre bei Laune zu halten.

https://valneva.com/press-release/valneva-reports-full-year-2024-results-and-provides-business-updates-and-outlook/?lang=de

Mar 20 (Reuters) - Valneva FY adjusted EBITDA EUR 32.9 million.

Guten Morgen ☕️☘️🙋‍♂️

New's sind da...